Longitudinal Clinical Outcomes Of Tau-Pet-Positive Individuals

Longitudinal clinical outcomes of tau-PET-positive individuals

Time gap between amyloid- and tau-PET positivity in preclinical disease

Limitations of [18F]flortaucipir tau-PET imaging

Optimization of Tau PET Imaging for Alzheimer’s Clinical Development

Current and future role of tau-PET in dementia daily practice

Dr. Ossenkoppele - Tau PET

Promise of tau-PET imaging for Alzheimer's disease

Tau ligands and the future of Tau PET imaging

Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease

Advantages of tau-PET compared to amyloid-PET

Realistic Strategies for Preventing Dementia; Frank Longo, MD, PhD

Stanford Medicine

Webinar | Amyloid PET in clinical practice: Interpretation and clinical significance

Australian Dementia Network

Tau PET imaging: the current landscape

Tau PET in the diagnosis of Alzheimer's disease/Hiroshi Matsuda's Neuroimaging Complete Case#8

U

Association of CSF and plasma biomarkers with longitudinal tau accumulation

The promise of 4R tau-PET tracer development

A new Aβ PET-based staging method

Next generation tau tracers: [18F]MK-6420 vs [18F]flortaucipir

Neuroimaging and Biomarkers: How Early Can We Diagnose Alzheimer's?